GP130 cytokines and bone remodelling in health and disease

키워드

참고문헌 (120)

1. Bravo, J., "Receptor recognition by gp130 cytokines", Embo J., 19, pp.2399~2411 (2000)
2. Yamasaki, K., "Cloning and expression of the human interleukin-6 (BSF-2", IFN beta 2) receptor, 1988, pp.241, 825~828
3. Hilton, D. J., "Cloning of a murine IL-11 receptor alpha-chain; requirement for gp130 for high affinity binding and signal transduction", Embo J., 13, pp.4765~4775 (1994)
4. Elson, G. C., "CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex", Nat. Neurosci., 3, pp.867~872 (2000)
5. Plun-Favreau, H., "The ciliary neurotrophic factor receptor alpha component in duces the secretion of and is required for functional responses to cardiotrophin-like cytokine", Embo J., 20, pp.1692~1703 (2001)
6. Hibi, M., "Molecular cloning and expression of an IL-6 signal transducer, gp130", Cell, 63, pp.1149~1157 (1990)
7. Gearing, D. P., "Leukemia inhibitory factor receptor is structurally related to the IL-6 signal transducer, gp130", Embo J., 10, pp.2839~2848 (1991)
8. Mosley, B., "Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation", J. Biol. Chem., 271, pp.32635~32643 (1996)
9. Lindberg, R. A., "Cloning and characterization of a specific receptor for mouse oncostatin M", Mol. Cell Biol., 18, pp.3357~3367 (1998)
10. Pflanz, S., "IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells", Immunity, 16, pp.779~790 (2002)
11. Hashimoto, Y., "Humanin inhibits neuronal cell death by interacting with a cytokine receptor complex or complexes involving CNTF receptor alpha", WSX-1, Mol. Biol. Cell, pp.2009, 20[DOI]
12. Sims, N. A., "Bone remodeling: multiple cellular interactions required for coupling of bone formation and resorption", Semin. Cell Dev. Biol., 19, pp.444~451 (2008)
13. Martin, T. J., "Bone remodeling: cellular and molecular events; in The Skeletal System", pp.297~316 (2009), Cold Spring Harbor Press
14. Walker, E. C., "Cardiotrophin-1 is an osteoclast-derived stimulus of bone formation required for normal bone remodeling", J. Bone Miner Res., 23, pp.2025~2032 (2008)
15. Pederson, L., "Regulation of bone formation by osteoclasts involves Wnt", BMP signaling and the chemokine sphingosine-1-phosphate, 2008, pp.통권 : 105, 20764~20769
16. van Bezooijen, R. L., "SOST", sclerostin, an osteocyte- derived negative regulator of bone formation, 2005, pp.16, 319~327
17. Kogianni, G., "Apoptotic bodies convey activity capable of initiating osteoclastogenesis and localised bone destruction", J. Bone Miner Res., 23, pp.915~927 (2008)
18. Laaksovirta, H., "Serum level of CNTF is elevated in patients with amyotrophic lateral sclerosis and correlates with site of disease onset", Eur. J. Neurol., 15, pp.355~359 (2008)
19. Waring, P., "Leukemia inhibitory factor levels are elevated in septic shock and various inflammatory body fluids", J. Clin. Invest, 90, pp.2031~2037 (1992)
20. Talwar, S., "An immunoluminometric assay for cardiotrophin-1: a newly identified cytokine is present in normal human plasma and is increased in heart failure", Biochem. Biophys. Res. Commun., 261, pp.567~571 (1999)
21. Daynes, R. A., "Altered regulation of IL-6 production with normal aging. Possible linkage to the age-associated decline in dehydroepiandrosterone and its sulfated derivative", J. Immunol., 150, pp.5219~5230 (1993)
22. Romas, E., "The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures", J. Exp. Med., 183, pp.2581~2591 (1996)
23. Manolagas, S. C., "The role of IL-6 type cytokines and their receptors in bone", Ann. N. Y. Acad. Sci., 840, pp.194~204 (1998)
24. Greenfield, E. M., "Adenyl cyclase and interleukin 6 are downstream effectors of parathyroid hormone resulting in stimulation of bone resorption", J. Clin. Invest., 96, pp.1238~1244 (1995)
25. Liang, J. D., "Immunohistochemical localization of selected early response genes expressed in trabecular bone of young rats given hPTH 1-34", Calcif. Tissue Int., 65, pp.369~373 (1999)
26. Tamura, T., "Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6", Proc. Natl. Acad. Sci. U.S.A., 통권 : 90, pp.11924~11928 (1993)
27. Richards, C. D., "Stimulation of osteoclast differentiation in vitro by mouse oncostatin M, leukaemia inhibitory factor, cardiotrophin-1 and interleukin 6: synergy with dexamethasone", Cytokine, 12, pp.613~621 (2000)
28. McGregor, N. E., "Ciliary neurotrophic factor inhibits bone formation and plays a sex-specific role in bone growth and remodeling", Calcif Tissue Int., 86, pp.261~270 (2010)
29. Horwood, N. J., "Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells", Endocrinology, 139, pp.4743~4746 (1998)
30. Fu, Q., "Parathyroid hormone controls receptor activator of NFkappaB ligand gene expression via a distant transcriptional enhancer", Mol. Cell Biol., 26, pp.6453~6468 (2006)
31. Atkins, G. J., "Coordinated cytokine expression by stromal and hematopoietic cells during human osteoclast formation", Bone, 26, pp.653~661 (2000)
32. Shin, H. I., "Gp130-mediated signaling is necessary for normal osteoblastic function in vivo and in vitro", Endocrinology, 145, pp.1376~1385 (2004)
33. Girasole, G., "Interleukin-11: a new cytokine critical for osteoclast development", J. Clin. Invest., 93, pp.1516~1524 (1994)
34. Gorny, G., "IL-6, LIF, and TNF-alpha regulation of GM-CSF inhibition of osteoclastogenesis in vitro", Exp. Cell Res., 294, pp.149~158 (2004)
35. Sims, N. A., "Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways", J. Clin. Invest, 113, pp.379~389 (2004)
36. Sims, N. A., "Interleukin-11 receptor signaling is required for normal bone remodeling", J. Bone Miner Res., 20, pp.1093~1102 (2005)
37. Kamiya, S., "Effects of IL-23 and IL-27 on osteoblasts and osteoclasts: inhibitory effects on osteoclast differentiation", J. Bone Miner Metab., 25, pp.277~285 (2007)
38. Kawasaki, K., "Osteoclasts are present in gp130-deficient mice", Endocrinology, 138, pp.4959~4965 (1997)
39. Poli, V., "Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion", Embo J., 13, pp.1189~1196 (1994)
40. Grey, A., "A role for interleukin-6 in parathyroid hormone-induced bone resorption in vivo", Endocrinology, 140, pp.4683~4690 (1999)
41. Bozec, A., "Osteoclast size is controlled by Fra-2 through LIF", LIF-receptor signalling and hypoxia, 2008, pp.454, 221~225
42. Ware, C. B., "Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death", Development, 121, pp.1283~1299 (1995)
43. Walker, E. C., "Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice", J. Clin. Invest, 120, pp.582~592 (2010)
44. Bellido, T., "Activation of the Janus kinase", STAT (signal transducer and activator of transcription) signal transduction pathway by interleukin-6-type cytokines promotes osteoblast differentiation, 1997, pp.138, 3666~3676
45. Kitamura, H., "Bone marrow neutrophilia and suppressed bone turnover in human interleukin-6 transgenic mice. A cellular relationship among hematopoietic cells, osteoblasts, and osteoclasts mediated by stromal cells in bone marrow", Am. J. Pathol., 147, pp.1682~1692 (1995)
46. De Benedetti, F., "Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system", Arthritis. Rheum., 54, pp.3551~3563 (2006)
47. Li, X., "Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis", J. Bone Miner Res., 24, pp.578~588 (2009)
48. Keller, H., "SOST is a target gene for PTH in bone", Bone, 37, pp.148~158 (2005)
49. Robling, A. G., "Mechanical stimulation in vivo reduces osteocyte expression of sclerostin", J. Musculoskelet Neuronal Interact, 6, pp.354~ (2006)
50. Jenkins, B. J., "Imbalanced gp130-dependent signaling in macrophages alters macrophage colony-stimulating factor responsiveness via regulation of c-fms expression", Mol. Cell Biol., 24, pp.1453~1463 (2004)
51. Dagoneau, N., "Null leukemia inhibitory factor receptor (LIFR) mutations in Stuve-Wiedemann", Schwartz-Jampel type 2 syndrome, 2004, pp.74, 298~305
52. Sims, N. A., "gp130 signaling in bone cell biology: multiple roles revealed by analysis of genetically altered mice", Mol. Cell Endocrinol., 310, pp.30~39 (2009)
53. Qi, L., "Interleukin-6 genetic variability and adiposity: associations in two prospective cohorts and systematic review in 26,944 individuals", J. Clin. Endocrinol. Metab., 92, pp.3618~3625 (2007)
54. Takacs, I., "Sib pair linkage and association studies between bone mineral density and the interleukin-6 gene locus", Bone, 27, pp.169~173 (2000)
55. Tsukamoto, K., "Association of radial bone mineral density with CA repeat polymorphism at the interleukin 6 locus in postmenopausal Japanese women", J. Hum. Genet., 44, pp.148~151 (1999)
56. Ogura, N., "Stimulation of interleukin-6 production of periodontal ligament cells by Porphyromonas endodontalis lipopolysaccharide", Biochem. Med. Metab. Biol., 53, pp.130~136 (1994)
57. Barkhordar, R. A., "Detection of interleukin-6 in human dental pulp and periapical lesions", Endod. Dent. Traumatol., 15, pp.26~27 (1999)
58. Johnson, R. B., "Interleukin-11 and IL-17 and the pathogenesis of periodontal disease", J. Periodontol., 75, pp.37~43 (2004)
59. Kawashima, N., "Expression of bone-resorptive and regulatory cytokines in murine periapical inflammation", Arch. Oral. Biol., 44, pp.55~66 (1999)
60. Tsai, C. H., "Immunohistochemical localization of oncostatin M in epithelialized apical periodontitis lesions", Int. Endod. J., 41, pp.772~776 (2008)
61. Lin, S. J., "Measurement of gp130 cytokines oncostatin M and IL-6 in gingival crevicular fluid of patients with chronic periodontitis", Cytokine, 30, pp.160~167 (2005)
62. Pradeep, A. R., S, T. M, "Serum levels of oncostatin M (a gp 130 cytokine): an inflammatory biomarker in periodontal disease", Biomarkers, 15, pp.277~282 (2010)
63. Gravallese, E. M., "Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis", Am. J. Pathol., 152, pp.943~951 (1998)
64. Romas, E., "Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis", Arthritis Rheum, 43, pp.821~826 (2000)
65. Scott, D. L., "Prognostic factors in early rheumatoid arthritis", Rheumatology (Oxford), 39(1), pp.24~29 (2000)
66. Pettit, A. R., "RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis", Rheumatology (Oxford), 45, pp.1068~1076 (2006)
67. Horwood, N. J., "Activated T lymphocytes support osteoclast formation in vitro", Biochem. Biophys. Res. Commun., 265, pp.144~150 (1999)
68. Crotti, T. N., "Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis", Ann. Rheum. Dis., 61, pp.1047~1054 (2002)
69. Walsh, N. C., "Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis", J. Bone Miner Res., 24, pp.1572~1585 (2009)
70. Okamoto, H., "The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis", Arthritis. Rheum., 40, pp.1096~1105 (1997)
71. Kotake, S., "Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation", J. Bone Miner Res., 11, pp.88~95 (1996)
72. Nowell, M. A., "Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130", J. Immunol., 171, pp.3202~3209 (2003)
73. Al-Awadhi, A., "Serum concentrations of interleukin 6, osteocalcin, intact parathyroid hormone, and markers of bone resorption in patients with rheumatoid arthritis", J. Rheumatol., 26, pp.1250~1256 (1999)
74. Walsh, N. C., "Rheumatic diseases: the effects of inflammation on bone", Immunol. Rev., 208, pp.228~251 (2005)
75. Fonseca, J. E., "Interleukin-6 as a key player in systemic inflammation and joint destruction", Autoimmun. Rev., 8, pp.538~542 (2009)
76. Takagi, N., "Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis", Arthritis. Rheum., 41, pp.2117~2121 (1998)
77. Kato, A., "Early effects of tocilizumab on bone and bone marrow lesions in a collagen-induced arthritis monkey model", Exp. Mol. Pathol., 84, pp.262~270 (2008)
78. Jones, G., "Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study", Ann. Rheum. Dis., 69, pp.88~96 (2010)
79. Plater-Zyberk, C., "Amelioration of arthritis in two murine models using antibodies to oncostatin M", Arthritis. Rheum., 44, pp.2697~2702 (2001)
80. Field, M., "Interleukin-6 localisation in the synovial membrane in rheumatoid arthritis", Rheumatol. Int., 11, pp.45~50 (1991)
81. Chu, C. Q., "Detection of cytokines at the cartilage", pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair, 1992, pp.31, 653~661
82. Wong, P. K., "Interleukin-6 modulates production of T lymphocytederived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis", Arthritis. Rheum., 54, pp.158~168 (2006)
83. Mihara, M., "Evidence for the role of Th17 cell inhibition in the prevention of autoimmune diseases by anti-interluekin-6 receptor antibody", Biofactors, 35, pp.47~51 (2009)
84. Fujimoto, M., "Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses", Arthritis. Rheum., 58, pp.3710~3719 (2008)
85. Benjamin, M., "The "enthesis organ" concept: why enthesopathies may not present as focal insertional disorders", Arthritis. Rheum., 50, pp.3306~3313 (2004)
86. McGonagle, D., "Imaging the joint and enthesis: insights into pathogenesis of psoriatic arthritis", Ann. Rheum. Dis., 64(2), pp.ii58~ii60 (2005)
87. McGonagle, D., "The concept of a "synovio-entheseal complex" and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond", Arthritis. Rheum., 56, pp.2482~2491 (2007)
88. Benjamin, M., "Histopathologic changes at "synovio-entheseal complexes" suggesting a novel mechanism for synovitis in osteoarthritis and spondylarthritis", Arthritis. Rheum., 56, pp.3601~3609 (2007)
89. Lories, R. J., "Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis", J. Clin. Invest., 115, pp.1571~1579 (2005)
90. Diarra, D., "Dickkopf-1 is a master regulator of joint remodeling", Nat. Med., 13, pp.156~163 (2007)
91. Appel, H., "Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis", Arthritis. Rheum., 60, pp.3257~3262 (2009)
92. Partsch, G., "Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid", J. Rheumatol., 24, pp.518~523 (1997)
93. Gratacos, J., "Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity", Br. J. Rheumatol., 33, pp.927~931 (1994)
94. Hayer, S., "Interleukin 6 is not a crucial regulator in an animal model of tumour necrosis factor-mediated bilateral sacroiliitis", Ann. Rheum. Dis., 69, pp.1403~1406 (2010)
95. Dieppe, P. A., "Pathogenesis and management of pain in osteoarthritis", Lancet, 365, pp.965~973 (2005)
96. Sakao, K., "Osteoblasts derived from osteophytes produce interleukin-6, interleukin-8, and matrix metalloproteinase-13 in osteoarthritis", J. Bone Miner Metab., 27, pp.412~423 (2009)
97. Durigova, M., "Mechanism of proteoglycan aggregate degradation in cartilage stimulated with oncostatin M", Osteoarthritis Cartilage, 16, pp.98~104 (2008)
98. Langdon, C., "Murine oncostatin M stimulates mouse synovial fibroblasts in vitro and induces inflammation and destruction in mouse joints in vivo", Am. J. Pathol., 157, pp.1187~1196 (2000)
99. de Hooge, A. S., "Adenoviral transfer of murine oncostatin M elicits periosteal bone apposition in knee joints of mice, despite synovial inflammation and up-regulated expression of interleukin-6 and receptor activator of nuclear factor-kappa B ligand", Am. J. Pathol., 160, pp.1733~1743 (2002)
100. Karsdal, M. A., "Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity", Arthritis. Res. Ther., 10, pp.R63~ (2008)
101. de Hooge, A. S., "Male IL-6 gene knock out mice developed more advanced osteoarthritis upon aging", Osteoarthritis. Cartilage., 13, pp.66~73 (2005)
102. Upadhyay, A., "Role of a LIF antagonist in LIF and OSM induced MMP-1, MMP-3, and TIMP-1 expression by primary articular chondrocytes", Cytokine, 46, pp.332~338 (2009)
103. Fan, Z., "IL-1beta induction of IL-6 and LIF in normal articular human chondrocytes involves the ERK, p38 and NFkappaB signaling pathways", Cytokine, 28, pp.17~24 (2004)
104. Rowan, A. D., "Synergistic effects of glycoprotein 130 binding cytokines in combination with interleukin-1 on cartilage collagen breakdown", Arthritis. Rheum., 44, pp.1620~1632 (2001)
105. Gao, Y., "Expression of IL-6 receptor and GP130 in mouse bone marrow cells during osteoclast differentiation", Bone, 22, pp.487~493 (1998)
106. Allan, E. H., "Osteoblasts display receptors for and responses to leukemia-inhibitory factor", J. Cell Physiol., 145, pp.110~119 (1990)
107. Udagawa, N., "Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors", J. Exp. Med., 182, pp.1461~1468 (1995)
108. Bellido, T., "Detection of receptors for interleukin-6, interleukin-11, leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in bone marrow stromal", osteoblastic cells, 1996, pp.97, 431~437
109. Dame, J. B., "The distribution of receptors for the pro-inflammatory cytokines interleukin (IL)-6 and IL-8 in the developing human fetus", Early Hum. Dev., 58, pp.25~39 (2000)
110. Legendre, F., "JAK", STAT but not ERK1, soluble IL-6R down-regulation of Type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a down-regulation of SOX9 expression, pp.J. Biol. Chem., 2003[DOI]
111. Nowell, M. A., "Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis", Arthritis. Rheum., 54, pp.2084~2095 (2006)
112. Hashizume, M., "IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17", Rheumatology (Oxford), 47, pp.1635~1640 (2008)
113. Wong, C., "Effects of inflammatory cytokine IL-27 on the activation of fibroblast-like synoviocytes in rheumatoid arthritis", Arthritis Res. Ther., 12 (2010)
114. Ishimi, Y., "IL-6 is produced by osteoblasts and induces bone resorption", J. Immunol., 145, pp.3297~3303 (1990)
115. Ishimi, Y., "Leukemia inhibitory factor", differentiation-stimulating factor (LIF, J. Cell Physiol., pp.1992, 152[DOI]
116. Liu, F., "Expression of leukemia inhibitory factor (LIF)", interleukin-6 family cytokines and receptors during in vitro osteogenesis: differential regulation by dexamethasone and LIF, 2002, pp.31, 212~219
117. Guerne, P. A., "IL-6 production by human articular chondrocytes. Modulation of its synthesis by cytokines, growth factors, and hormones in vitro", J. Immunol., 144, pp.499~505 (1990)
118. Maier, R., "Interleukin-11, an inducible cytokine in human articular chondrocytes and synoviocytes, stimulates the production of the tissue inhibitor of metalloproteinases", J. Biol. Chem., 268, pp.21527~21532 (1993)
119. Grimaud, E., "Leukaemia inhibitory factor (lif) is expressed in hypertrophic chondrocytes and vascular sprouts during osteogenesis", Cytokine, 20, pp.224~230 (2002)
120. Sheng, Z., "Cardiotrophin-1 displays early expression in the murine heart tube and promotes cardiac myocyte survival", Development, 122, pp.419~428 (1996)

관련 논문AI추천